Melden Sie sich bitte kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Melden Sie sich bitte kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Basal­zell­kar­zi­nom
Cemiplimab, Libtayo, PD-1, Sonidegib, Odomzo, Hh, Vismodegib, Erivedge
Cholangio­­kar­­zi­nom
Durvalumab, Imfinzi, PD-L1, Futibatinib, Lytgobi, FGF(R), Ivosidenib, Tibsovo, IDH1, Pemigatinib, Pemazyre, Zanidatamab, Ziihera, HER2
Kolo­rektal­kar­zinom (CRC)
Kolorektalkarzinom, Aflibercept, Zaltrap, VEGF(R), PIGF, Bevacizumab, Avastin, Abevmy, Avzivi, Aybintio, Mvasi, Oyavas, Zirabev, Cetuximab, Erbitux, EGF(R), Encorafenib, Braftovi, BRAF, Fruquintinib, Fruzaqla, Ipilimumab, Yervoy, CTLA-4, Nivolumab, Opdivo, PD-1, Panitumumab, Vectibix, Pembrolizumab, Keytruda, Ramucirumab, Cyramza, Regorafenib, Stivarga, KIT, RET, PDGF(R), FGF(R)
Endometrium­kar­zi­nom
Dostarlimab, Jemperli, PD-1, Durvalumab, Imfinzi, PD-L1, Lenvatinib, Kisplyx, Lenvima, VEGF(R), FGF(R), PDGF(R), KIT, RET, Olaparib, Lynparza, PARP, Pembrolizumab, Keytruda
Gastrointestinale Stromatumoren (GIST)
Gastrointestinale Stromatumoren, CD117-positiv, Avapritinib, Ayvakyt, PDGF(R), KIT, Regorafenib, Stivarga, VEGF(R), RET, BRAF, FGF(R), Ripretinib, Qinlock, TIE2, Sunitinib, Sutent, Sunitinib Accord
Hepatozelluläres Karzinom (HCC)
Hepatozelluläres Karzinom, Atezolizumab, Tecentriq, PD-L1, Cabozantinib, Cabometyx, Cometriq, MET, VEGF(R), RET, KIT, ROS, Durvalumab, Imfinzi, Ipilimumab, Yervoy, CTLA-4, Lenvatinib, Kisplyx, Lenvima, FGF(R), PDGF(R), Nivolumab, Opdivo, PD-1, Ramucirumab, Cyramza, Regorafenib, Stivarga, BRAF, Sorafenib, Nexavar, Tremelimumab, Imjudo
Magen, GEJ, Ösophagus
Magen/GEJ/Ösophagus, Ipilimumab, Yervoy, CTLA-4, Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda, Pembrolizumab, Ramucirumab, Cyramza, VEGF(R), Tislelizumab, Tevimbra, Tislelizumab, Toripalimab, Loqtorzi, Trastuzumab, Herceptin, Herwenda, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac, HER2, Trastuzumab-Deruxtecan, Enhertu, Zolbetuximab, Vyloy, CLDN18.2
Klein­zelliges Bronchial­­kar­­zi­nom (SCLC)
Atezolizumab, Tecentriq, PD-L1, Durvalumab, Imfinzi, Serplulimab, Hetronifly, PD-1, Tislelizumab, Tevimbra
Kutanes Platten­epithel­kar­zinom
Mammakarzinom (MCa)
MCa, Abemaciclib, Verzenios, CDK4/6, Alpelisib, Piqray, PI3Kα, Atezolizumab, Tecentriq, PD-L1, Bevacizumab, Avastin, Abevmy, Avzivi, Aybintio, Mvasi, Oyavas, Zirabev, VEGF(R), Capivasertib, Truqap, AKT, Datopotamab deruxtecan, Datroway, Trop-2, Everolimus, Afinitor, mTOR, Lapatinib, Tyverb, EGF(R), HER2, Neratinib, Nerlynx, Olaparib, Lynparza, PARP, Palbociclib, Ibrance, Pembrolizumab, Keytruda, PD-1, Pertuzumab, Perjeta, Phesgo (Pertuzumab + Trastuzumab), Pertuzumab, Ribociclib, Kisqali, Sacituzumab Govitecan, Trodelvy, Talazoparib, Talzenna, Trastuzumab, Herceptin, Herwenda, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac, Trastuzumab, Trastuzumab Emtansin, Kadcyla, Trastuzumab Emtansin, Trastuzumab-Deruxtecan, Enhertu, Tucatinib, Tukysa
Merkel­zell­kar­zinom (MCC)
Merkelzellkarzinom, Avelumab, Bavencio, PD-L1, Retifanlimab, Zynyz, PD-1
Melanom
Binimetinib, Mektovi, MEK, Cobimetinib, Cotellic, Dabrafenib, Tafinlar, BRAF, Encorafenib, Braftovi, Ipilimumab, Yervoy, CTLA-4, Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda, Relatlimab, Opdualag, LAG-3, Tebentafusp, Kimmtrak, CD3, gp100-Peptid, Trametinib, Mekinist, Vemurafenib, Zelboraf
Neuroendokrine Tumoren (NET)
Neuroendokrine Tumoren, Everolimus, Afinitor, mTOR, Everolimus, Sunitinib, Sutent, Sunitinib Accord, PDGF(R), VEGF(R), KIT, RET
Nicht­klein­zelliges Bron­chial­kar­zinom (NSCLC)
Nichtkleinzelliges Bronchialkarzinom, Afatinib, Giotrif, EGF(R), HER2, Alectinib, Alecensa, ALK, RET, Amivantamab, Rybrevant, MET, Atezolizumab, Tecentriq, PD-L1, Bevacizumab, Avastin, Abevmy, Avzivi, Aybintio, Mvasi, Oyavas, Zirabev, VEGF(R), Binimetinib, Mektovi, MEK, Brigatinib, Alunbrig, ROS1, IGF-1R, Capmatinib, Tabrecta, Cemiplimab, Libtayo, PD-1, Ceritinib, Zykadia, Crizotinib, Xalkori, ROS, Dabrafenib, Tafinlar, BRAF, Dacomitinib, Vizimpro, Durvalumab, Imfinzi, Encorafenib, Braftovi, Entrectinib, Rozlytrek, TRK, Erlotinib, Tarceva, Gefitinib, Iressa, Ipilimumab, Yervoy, CTLA-4, Lazertinib, Lazcluze, Lorlatinib, Lorviqua, Nintedanib, Vargatef, PDGF(R), FGF(R), Nivolumab, Opdivo, Osimertinib, Tagrisso, Pembrolizumab, Keytruda, Ramucirumab, Cyramza, Repotrectinib, Augtyro, Selpercatinib, Retsevmo, Sotorasib, Lumykras, KRAS G12C, Sugemalimab, Cejemly, Tepotinib, Tepmetko, Tislelizumab, Tevimbra, Trametinib, Mekinist, Trastuzumab-Deruxtecan, Enhertu, Tremelimumab, Imjudo
Ovarial-, Tuben-, Peritoneal­kar­zinom
Bevacizumab, Avastin, Abevmy, Avzivi, Aybintio, Mvasi, Oyavas, Zirabev, VEGF(R), Mirvetuximab-Soravtansin, Elahere, FRα, Niraparib, Akeega (Niraparib/Abirateronacetat), Zejula, PARP, Olaparib, Lynparza, Rucaparib, Rubraca
Pankreas­karzinom
Erlotinib, Tarceva, EGF(R), Olaparib, Lynparza, PARP
Pleurameso­theliom
Ipilimumab, Yervoy, CTLA-4, Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda
Prostatakarzinom
Enzalutamid, Xtandi, Enzalutamid Viatris, AR, Lutetium(Lu-177)vipivotidtetraxetan, Pluvicto, PSMA, Olaparib, Lynparza, PARP, Talazoparib, Talzenna
Nieren­zell­kar­zi­nom (RCC)
Nierenzellenkarzinom, renal cell carcinoma, Avelumab, Bavencio, PD-L1, Axitinib, Axitinib Accord, Inlyta, VEGF(R), Belzutifan, Welireg, HIF-2α, Bevacizumab, Avastin, Abevmy, Avzivi, Aybintio, Mvasi, Oyavas, Zirabev, Cabozantinib, Cabometyx, Cometriq, MET, RET, KIT, ROS, Everolimus, Afinitor, mTOR, Ipilimumab, Yervoy, CTLA-4, Lenvatinib, Kisplyx, Lenvima, FGF(R), PDGF(R), Nivolumab, Opdivo, PD-1, Pazopanib, Votrient, Pembrolizumab, Keytruda, Sorafenib, Nexavar, BRAF, Sunitinib, Sutent, Sunitinib Accord, Temsirolimus, Torisel, Tivozanib, Fotivda
Kopf-Hals-Tumoren (SCCHN)
Kopf-Hals-Tumoren, Cetuximab, Erbitux, EGF(R), Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda, Tislelizumab, Tevimbra, Toripalimab, Loqtorzi
Schild­drüsen­kar­zi­nom
Cabozantinib, Cabometyx, Cometriq, MET, VEGF(R), RET, KIT, ROS, Lenvatinib, Kisplyx, Lenvima, FGF(R), PDGF(R), Selpercatinib, Retsevmo, Sorafenib, Nexavar, BRAF, Vandetanib, Caprelsa, EGF(R)
Urothelkarzinom
Atezolizumab, Tecentriq, PD-L1, Avelumab, Bavencio, Enfortumab Vedotin, Padcev, Nectin-4, Erdafitinib, Balversa, FGF(R), Nivolumab, Opdivo, PD-1, Pembrolizumab, Keytruda
Weich­gewebs­sarkom (STS)
STS, DFSP, Imatinib, Glivec, Accord, Teva, BCR/ABL, KIT, PDGF(R), Pazopanib, Votrient, VEGF(R)
Zervixkarzinom
Bevacizumab, Avastin, Abevmy, Avzivi, Aybintio, Mvasi, Oyavas, Zirabev, VEGF(R), Cemiplimab, Libtayo, PD-1, Pembrolizumab, Keytruda, Tisotumab vedotin, Tivdak, TF
In Kooperation mit